Natalizumab: Benefit outweighs risk in selected patients with multiple sclerosis

J. Theodore Phillips; Elliot Frohman

doi:10.1177/1756285608099124

Natalizumab: Benefit outweighs risk in selected patients with multiple sclerosis

J. Theodore Phillips, Elliot Frohman

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	151-153
Number of pages	3
Journal	Therapeutic Advances in Neurological Disorders
Volume	1
Issue number	3
DOIs	https://doi.org/10.1177/1756285608099124
State	Published - Nov 2008

ASJC Scopus subject areas

Pharmacology
Neurology
Clinical Neurology

Access to Document

10.1177/1756285608099124

Cite this

@article{653205dfb8c64433ae3ba5e2be456395,

title = "Natalizumab: Benefit outweighs risk in selected patients with multiple sclerosis",

author = "Phillips, {J. Theodore} and Elliot Frohman",

year = "2008",

month = nov,

doi = "10.1177/1756285608099124",

language = "English (US)",

volume = "1",

pages = "151--153",

journal = "Therapeutic Advances in Neurological Disorders",

issn = "1756-2856",

publisher = "SAGE Publications Ltd",

number = "3",

}

TY - JOUR

T1 - Natalizumab

T2 - Benefit outweighs risk in selected patients with multiple sclerosis

AU - Phillips, J. Theodore

AU - Frohman, Elliot

PY - 2008/11

Y1 - 2008/11

UR - http://www.scopus.com/inward/record.url?scp=84993790660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993790660&partnerID=8YFLogxK

U2 - 10.1177/1756285608099124

DO - 10.1177/1756285608099124

M3 - Editorial

C2 - 21180572

AN - SCOPUS:84993790660

SN - 1756-2856

VL - 1

SP - 151

EP - 153

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

IS - 3

ER -

Natalizumab: Benefit outweighs risk in selected patients with multiple sclerosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this